a nanofiber comprising a peptide GPCR modulator conjugated to a lipophilic moiety where in the peptide-lipophilic moiety conjugate comprises a poly(proline) type II helix structure.

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

A patch for treating vascular ulcers caused by excessive enzymatic activity may include a substrate configured to span a vascular ulcer as well as a linking material that is disposed relative to the substrate and has an affinity for an enzyme involved in causing the vascular ulcer. A magnetic material may be coupled to the linking material. In some cases, the enzymes involved in causing the vascular ulcer may become coupled to the linking material and thus become coupled to the magnetic material so that that the enzymes can be removed by applying a magnetic field in the proximity of the vascular ulcer. The enzymes may include matrix metalloproteinases.

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Provided herein are peptide amphiphiles (PAs). In some embodiments, provided herein are targeting PAs comprising a PA backbone and a targeting moiety. In some embodiments, provided herein are therapeutic PAs comprising a PA backbone and a therapeutic agent. In some embodiments, the peptide amphiphiles are co-assembled into nanofibers. In some embodiments, the nanofibers may be used for the treatment of atherosclerosis or related disease.

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.